Related Experiment Video
Updated: May 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Pharmacologic interactions of multidrug therapy for dyslipidemia
1Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, 9 Gates Building 3400 Spruce Street, Philadelphia, PA 19103, USA. nidhi.mehta@uphs.upenn.edu
Abstract:
Despite the best available medical therapy inclusive of statins, substantial residual risk remains for atherothrombotic cardiovascular disease. Non-statin lipid-lowering therapy may help address this critical unmet need through reduction of the levels of low-density lipoprotein and other atherogenic lipoproteins. In the past few years, several landmark trials have provided important information regarding the efficacy and safety of non-statin therapy for dyslipidemia and cardiovascular risk reduction.
Related Concept Videos
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Drug Interactions
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Atherosclerosis III: Management
